Why Research-Only Oncology Sites Are Built Differently

Research is the primary workflow

In a mixed clinical and research environment, urgent routine-care demands may compete with research appointments, staff time, rooms, and diagnostic resources. A research-only model can allocate these resources expressly for study work. That may include rooms suitable for extended visits, designated monitoring space, controlled investigational product workflows, sample-processing equipment, secure record systems, and staff whose daily responsibilities are protocol-centered.

The benefit appears when the operating system matches the protocol. A dedicated site without the appropriate disease expertise, qualified personnel, pharmacy capability, or participant safeguards is still not the right site.

Feasibility can be operational, not aspirational

Reliable feasibility requires more than estimating the number of people with a diagnosis. A research-only site can bring operational owners into the evaluation early:

• •The investigator evaluates the clinical population and protocol rationale.
• •Operations maps the visit schedule, staffing, room use, and competing studies.
• •Regulatory assesses submission dependencies and document readiness.
• •Pharmacy reviews preparation, storage, accountability, blinding, and administration requirements.
• •Laboratory staff review kits, processing times, centrifugation, freezing, shipping, and weekend needs.
• •Data staff assess source design, electronic systems, and query workload.
• •Patient access teams examine referral sources, records flow, and likely screen-failure points.

This multidisciplinary review can expose risks before a site commits to a recruitment projection.

Investigator access is designed into the model

ICH Good Clinical Practice places responsibility for trial conduct at the investigator site with the investigator. Delegation is necessary, but it does not eliminate oversight. A research-only model should create protected investigator time for feasibility, training, participant evaluation, safety review, sponsor communication, deviation assessment, and data interpretation.

Sponsors and CROs can test this during qualification. Who makes clinical decisions? How quickly can the investigator review an eligibility ambiguity or emerging safety issue? What is the escalation pathway after hours? How is oversight documented?

Patient access is an operating capability

Patient access is not the same as advertising or a large contact list. It includes disease-specific outreach, relationships with referring clinicians, secure record acquisition, medically informed pre-screening, timely follow-up, culturally and linguistically appropriate communication, and respectful closure when a study is not relevant.

A research-only site can create a defined path from inquiry to protocol review. That path should protect patients from being told that they “match” before the required evidence is available. It should also preserve continuity with treating physicians and avoid delaying appropriate care.

Complexity requires choreography

Early-phase oncology protocols may combine dose escalation, intensive pharmacokinetic sampling, premedication, prolonged observation, research biopsies, rapidly changing safety information, and narrow visit windows. Execution depends on coordinated handoffs:

• •Eligibility evidence is complete before enrollment.
• •Orders align with the current protocol and dose level.
• •Pharmacy, nursing, laboratory, and investigator schedules align.
• •Samples move according to time and temperature requirements.
• •Adverse events and dose-limiting toxicities are assessed and escalated promptly.
• •Source data support accurate and timely entry.

The organization should rehearse these handoffs before the first participant visit.

What Sponsors and CROs should verify

During qualification, ask for concrete evidence:

• •Current workload by investigator and key role
• •Role-specific training and delegation controls
• •Pharmacy and laboratory capability matched to the protocol
• •Backup coverage and after-hours escalation
• •Recent performance trends and issue-resolution examples
• •Quality management, internal review, and CAPA processes
• •Referral and patient-access pathways relevant to the indication
• •Inspection, audit, and monitoring readiness

The goal is not to eliminate every risk. It is to confirm that the site understands its critical risks and has proportionate controls.

Our FCTG approach

At Florida Clinical Trials Group, we are structured as a research-focused oncology platform. Our physician investigators remain directly engaged, while our centralized research team supports community referral relationships, organized patient access, protocol-specific feasibility, and Quality by Design. Before we commit to a study, our clinical and operational leaders assess the protocol against our investigator expertise, staff capacity, facilities, competing workload, and the study's actual demands.